

AstraZeneca AB, AstraZeneca UK Limited, and AstraZeneca Pharmaceuticals LP (hereinafter collectively “AstraZeneca”), and Teva Pharmaceuticals USA, Inc. (“Teva”), the parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of this action and have set forth those terms and conditions in a Settlement Agreement (the “Settlement Agreement”). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in this action as follows:

IT IS this 29<sup>th</sup> day of January 2018:

ORDERED, ADJUDGED AND DECREEED as follows:

1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties.
2. As used in this Consent Judgment, (i) the term “Teva Product” shall mean a drug product sold, offered for sale or distributed pursuant to New Drug Application No.


210063 (and defined in greater detail in the Settlement Agreement); and (ii) the term "Affiliate" shall mean, with respect to a Party, any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party. For purposes of this definition, "control" means (a) ownership, directly or through one or more intermediaries, of (i) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (ii) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the board of directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.

3. Except as specifically authorized pursuant to the Settlement Agreement, Teva, including any of its Affiliates, successors and assigns, is enjoined from making, having made, using, selling, offering to sell, importing or distributing of the Teva Product.

4. Compliance with this Consent Judgment may be enforced by AstraZeneca and Teva and their successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.

  
Renee M. Bumb, U.S.D.J.

We hereby consent to the form and entry of this Order:

s/John E. Flaherty

Lisa B. Pensabene  
Filko Prugo  
Caitlin P. Hogan  
Eberle Schultz  
O'MELVENY & MYERS LLP  
Times Square Tower  
7 Times Square  
New York, NY 10036  
(212) 326-4481

John E. Flaherty  
Ravin R. Patel  
MCCARTER & ENGLISH, LLP  
Four Gateway Center  
100 Mulberry Street  
Newark, NJ 07102  
(973) 622-4444

*Attorneys for AstraZeneca AB, AstraZeneca  
UK Limited, and AstraZeneca Pharmaceuticals  
LP*

s/James S. Richter

James S. Richter  
Keiyana B. Fordham  
WINSTON & STRAWN LLP  
One Riverfront Plaza  
Suite 730  
Newark, NJ 07102  
973-848-7648

*Attorneys for Teva Pharmaceuticals USA, Inc.*